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The aims of this study were to check whether different biomarkers of inflammatory, apoptotic, immunological or
lipid pathways had altered their expression in the occluded popliteal artery (OPA) compared with the internal
mammary artery (IMA) and femoral vein (FV) and to examine whether glycemic control influenced the expression
of these genes. The study included 20 patients with advanced atherosclerosis and type 2 diabetes mellitus, 15 of
whom had peripheral arterial occlusive disease (PAOD), from whom samples of OPA and FV were collected. PAOD
patients were classified based on their HbA1c as well (HbA1c≤ 6.5) or poorly (HbA1c> 6.5) controlled patients.
Controls for arteries without atherosclerosis comprised 5 IMA from patients with ischemic cardiomyopathy (ICM).
mRNA, protein expression and histological studies were analyzed in IMA, OPA and FV. After analyzing 46 genes,
OPA showed higher expression levels than IMA or FV for genes involved in thrombosis (F3), apoptosis (MMP2,
MMP9, TIMP1 and TIM3), lipid metabolism (LRP1 and NDUFA), immune response (TLR2) and monocytes adhesion
(CD83). Remarkably, MMP-9 expression was lower in OPA from well-controlled patients. In FV from diabetic patients
with HbA1c ≤6.5, gene expression levels of BCL2, CDKN1A, COX2, NDUFA and SREBP2 were higher than in FV from
those with HbA1c >6.5.
The atherosclerotic process in OPA from diabetic patients was associated with high expression levels of
inflammatory, lipid metabolism and apoptotic biomarkers. The degree of glycemic control was associated with
gene expression markers of apoptosis, lipid metabolism and antioxidants in FV. However, the effect of glycemic
control on pro-atherosclerotic gene expression was very low in arteries with established atherosclerosis.
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Cardiovascular diseases (CVD) are highly prevalent in
the general population, affecting most adults over
60 years of age. Vascular endothelium has unique
responses to hemodynamic forces. The flow and
hemodynamic forces are not uniform in the vascular sys-
tem. The endothelium of the vascular circulation is
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distribution, and reproduction in any mediumthan in other human tissues. Hemodynamic forces play
an important role in vascular diseases, especially in the
location of atheromas [1].
The pathophysiology of arterial thrombosis is different
from that of venous thrombosis. In the arteries there is
altered endothelium-platelet adhesion, greatly influ-
enced by hemodynamic forces, while the major factors
for venous thrombosis are the phenomena of slow or
stagnant blood flow, combined with hypercoagulability
situations [2].
Sustained flow with high shear stress upregulates gene
and then protein expression in endothelial cells, which
has a protective effect against the atherosclerotic process
[3]. In the venous system, a disturbed flow leads to in-
flammation and venous thrombosis, and therefore thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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eral arterial disease.
Atherosclerosis is associated with processes such as in-
flammation [4] lipid metabolism [5], apoptosis [6] and
the immune system responses [5]. Epidemiologic studies
show a consistent association between diabetes and car-
diovascular disease [7]. The influence of evaluating the
atherosclerosis process according to the effect of tight
glycemic control has been less convincing in clinical
trials [8]. Hyperglycemia could lead to vascular compli-
cations via several mechanisms. Hyperglycemia per se
activate transcription factors that modulate the expres-
sion of a number of genes in endothelial cells,
monocyte-macrophage and vascular smooth muscle cells
favoring atherosclerotic process.
In this study our aims were to determine whether dif-
ferent biomarkers (inflammatory, oncogenic, immuno-
logical or lipid) had altered gene expression in different
atherosclerotic blood vessels (artery vs. vein) and to
examine whether glycemic control influenced the ex-
pression of these genes.
Materials and methods
Subjects
All patients were hospitalized in the Cardiovascular
Surgery Department of Carlos Haya Hospital (Malaga,
Spain) between February 2007 and June 2008. Those
diagnosed with an advanced atherosclerotic process
and type 2 diabetes mellitus were recruited to this
study. Two types of vascular biopsies were collected
from patients with clinical stage IV peripheral arterial
occlusive disease and lower limb amputation (PAOD):
1) occluded popliteal artery (OPA) with atherosclerotic
plaque and 2) femoral vein (FV). Both the OPA and
the FV were obtained from the vascular package of
each patient (n = 15). Control arteries with no athero-
sclerosis consisted of internal mammary artery (IMA)
biopsies collected from 5 diabetic patients with good
glycemic control and severe ischemia due to ischemic
cardiomyopathy (ICM) who were undergoing coronary
revascularization.
Patients were included if they were aged 18–80 years
(all patients were over 60) and provided written
informed consent. Patients were excluded if they had
associated diseases such as alcoholism, drug addiction or
HIV. Individuals who refused to participate in the study
were considered losses.
We evaluated the presence of atherosclerotic risk fac-
tors using the definitions of the Spanish Society of
Hypertension (blood pressure, systolic ≥140 and/or dia-
stolic ≥90 mmHg), ADA (fasting blood glucose level
≥126 mg/dl), and the NCEP-ATP3 criteria (triglycerides
≥150 mg/dl and HDL cholesterol <40 mg/dl in men or
<50 mg/dl in women). A BMI (Kg/m2) >30 was usedfor the presence of obesity and patients were considered
to be smokers if they had smoked up to 6 months before
hospital admission. Anthropometric and biochemical
parameters included sex, age, waist circumference, sys-
tolic and diastolic blood pressure, glucose, HbA1c, total
cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol and triglycer-
ides. The HOMA (Homeostasis Model Assessment)
index, a method used to quantify insulin resistance and
beta-cell function, was also recorded. The approximating
equation for insulin resistance used a fasting blood sam-
ple, and was derived by use of the insulin-glucose prod-
uct, divided by a constant: (glucose x insulin)/405 where
glucose is given in mg/dL and insulin is given in μU/mL.
The patients had type 2 diabetes mellitus for
12 ± 7 years. Type 2 diabetes mellitus was diagnosed
according to the ADA definition (2010) by the presence
of repeated fasting glucose levels ≥126 mg/dl if the
patients were being treated with oral antidiabetic agents
or insulin at the time of the study or if their HbA1c was
>6.5%. This definition was corroborated with the
patient’s medical history in order to avoid misdiagnosis
due to stress hyperglycemia during hospital admission.
The patients with PAOD were divided into either well-
controlled or poorly-controlled groups, depending on
their glucose and HbA1c (Table 1). All the diabetic
patients were treated with metformin and 70% of the
poorly-controlled diabetic patients were treated with in-
sulin. The patients were admitted to the hospital 72 h
before surgery. Their treatment was usually modified in
order to prepare the patient for surgery. There was a
drug washout period of 12 h prior to blood collection.
Control patients (patients with ICM) were aged
63 ± 13 years and had similar baseline characteristics as
the patients with PAOD. Patient’s characteristics did not
significantly differ between the groups.
The study protocol complied with the principles of the
Helsinki Declaration. The study was approved by the
hospital ethics committee and all the patients gave writ-
ten informed consent to participate in the study.
Isolation of human mRNA from biopsies
Samples of OPA, FV and IMA vessels were homogenized
in ice using the Tripure Isolation Reagent (Roche Mo-
lecular Biochemicals, Barcelona, Spain) according to the
manufacturer’s instructions using a laboratory batch
mixer (T25-Ultra3-Turrax Basic; IkaR Laboratory
Equipment).
Real-time PCR
A total of 46 genes were studied in these vascular biop-
sies. The genes were classsified depending on the meta-
bolic pathway involved. Housekeepping genes: 18 S
and GAPDH. Lipid metabolism genes: PPARg, PTGS1
Table 1 Patient’s characteristics with CMI or PAOD and their characteristics when classified as well-controlled (HbA1c ≤
6.5) or poorly-controlled (HbA1c > 6.5) diabetic patients
PAOD Subjects
CMI Subjects PAOD Subjects DM2 with HbA1c ≤ 6.5 DM2 with HbA1c > 6.5
N (%) 5 (25.0) 15 (75.0) 6 (40.0) 9 (60.0)
Age (years) 63.2 ± 13.0 67.3 ± 14.2 73.8 ± 11.8 63.0 ± 14.6
Sex (Male/Female) (%) 5/0 12/3 5 (83.3)/2 (16.7) 7 (77.8)/2 (22.2)
Weight (Kg) 75.9 ± 10.1 68.7 ± 12.1 63.5 ± 11.3 72.1 ± 11.9
Waist circumference (cm) 94.5 ± 3.5 96.7 ± 8.7 96.5 ± 12.7 90.8 ± 19.2
BMI (kg/m2) 27.9 ± 3.5 25.3 ± 3.9 24.6 ± 4.4 25.7 ± 3.7
SBP/DBP (mmHg) 133/74 ± 24/14 150/76 ± 24/13 141/78 ± 21/6 155/75 ± 26/16
Glycemia (mg/dL) 105.2 ± 8.3 129.2 ± 48.1 96.2 ± 31.1 151.2 ± 32.6*
HbA1c (%) 6.2 ± 0.3 7.8 ± 1.8 6.0 ± 0.4 8.9 ± 1.3**
Creatinine (mg/dL) 1.0 ± 0.3 1.9 ± 0.9 1.2 ± 0.7 2.5 ± 1.7
Uric acid (mg/dL) 5.4 ± 1.4 4.5 ± 2.8 3.6 ± 2.0 5.3 ± 3.3
Total cholesterol (mg/dL) 135.8 ± 37.9 152.7 ± 55.6 126.5 ± 67.0 179.9 ± 61.1
LDL cholesterol (mg/dL) 81.8 ± 15.5 88.0 ± 28.12 73.4 ± 21.7 112.4 ± 52.2
HDL cholesterol (mg/dL) 32.4 ± 12.0 32.6 ± 13.8 32.3 ± 18.9 32.9 ± 9.0
Triglycerides (mg/dL) 201.0 [106.0-302.0] 122.0 [82.3-234.5] 116.5 [74.8-131.5] 210.5 [83.5-364.3]
GOT (U/l) 27.2 ± 9.8 34.23 ± 9.3 40.8 ± 46.5 28.6 ± 19.7
GPT(U/l) 53.2 ± 30.0 40.7 ±19.0 42.5 ± 20.5 39.1 ± 19.1
GGT (U/l) 30.2 ± 9.8 56.1 ± 7.1 89.3 ± 40.7 114.6 ± 132.8
Insulin (μUI/ml) 13.5 ± 9.3 11.8 ± 6.4 10.5 ± 5.8 12.6 ± 7.3
HOMA index 5.9 ± 4.6 4.1 ± 2.2 2.8 ± 1.6 5.3 ± 2.4
Hypertension (%) 21.4 73.3 66.7 77.8
Dyslipidemia (%) 57.1 85.7 83.3 87.5
Obesity (%) 16.7 33.3 33.3 33.3
Smoker (%) 33.3 13.3 11.1 22.2
Values are shown as mean ± SD (* p=0.02 vs well control; ** p=<0.0001 vs well control).
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SCARB1, OLR1, ABCA1, TFPI, USP9Y. Apoptotic genes:
CDKN1A, BCL2, BAX, Caspase 3, CD83, MMP2,
MMP3, MMP9, MMP13. Signal transduction genes:
CCL2 (MCP1), AKT1, VEGFA. Inflammatory genes: F3
(tF), CD34, AGER, CRP, Von Willebrand factor. Immune
reponse genes: CD86, TLR2, TLR4. Cytoskeleton regula-
tor genes: Endoglin, Actin A1, MMP10, MMP12,
TIMP1, TIMP3. Translation-transcription regulator
genes: SREBF1, SREBF2, Sp1, HIF1A, TP53, NKIRAS2.
cDNA was obtained from 1 μg RNA using the High
Capacity cDNA Archive Kit (Applied Biosystems, San
Francisco, California, EEUU). RNA purity was deter-
mined by measuring the A260/A280 ratio. RNAs with
ratios between 1.7 and 2 were considered adequate for
quantification of mRNA expression. cDNA synthesis
was obtained from 1 μg RNA using the protocol pro-
vided with the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Foster City, CA, USA).
Recombinant RNasin Ribonuclease Inhibitor (Applied)was added to prevent RNase-mediated degradation.
cDNA was stored at –20°C.
Gene expression analyses were performed at mRNA
level by Taqman Low-Density Array (TLDA). Pre-
designed TaqMan probe and primer sets for target genes
were chosen from an on-line catalogue (Applied). Once
selected, the sets were factory-loaded into the 384 wells
of the TLDA card which was configured into eight iden-
tical 24 gene sets in duplicate. Twenty-two genes were
chosen based on literature reviews of key molecules in
inflammation and immunology. Each set of genes also
contained two housekeeping genes, GAPDH and
18srRNA.
Five μl of single-stranded cDNA (equivalent to 100 ng
of total RNA) were mixed with 45 μl of nuclease-free
water and 50 μl of TaqMan Universal PCR Master Mix.
After gentle mixing and centrifugation, 100 μl of mixture
was transferred into a loading port on a TLDA card. The
card was centrifuged twice for 1 minute at 1100 rpm to
distribute the samples from the loading port into each
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Card Sample Block of an Applied Biosystems 7900HT
PCR system (Applied Biosystems). The thermal cycling
conditions were 2 min at 50°C and 10 min at 95°C, fol-
lowed by 40 cycles of 30 s at 97°C and 1 min at 59.7°C.
Expression levels were measured in duplicate. Only the
genes with reproducible amplification curves of both
duplicates were analyzed and are presented. TLDA cards
were analyzed with RQ documents and the RQ Manager
Software for automated data analysis. Gene expression
values (RQ) were calculated based on the ΔΔCt method.
Delta cycle threshold (Ct) values, defined as the point at
which the fluorescence rises above the background fluor-
escence, were calculated with SDS 2.3 software (Applied
Biosystems). A mixture of DNA from IMA was used as
a calibrator and the 18srRNA housekeeping gene was
the reference for normalization.
Western blot analysis
The proteins from IMA, FV and OPA biopsies were ana-
lyzed by western blot analysis as described previously
[9]. Blots were incubated with monoclonal antibodies
against human tF (ADI, Ref: 4501; dilution 1:1000;
American Diagnostica Inc., Stamford, Connecticut,
EEUU) and LRP-1 (RDI; PR-61067; Fitzgerald dilution
1:50; Fitzgerald Industries International, North Acton,
MA, USA). Equal proteins loading in each line was veri-
fied by staining filters with Ponceau and also by incubat-
ing blots with monoclonal antibodies against β-actin
(clone AC-15, Sigma). Western blot bands were quanti-
fied with a Chemi-doc (BioRad) using the Quantity One
1-D Analysis Software. Results are expressed as arbitrary
units (AU) that refer to units of intensity/mm2.
Histological analysis
The vascular biopsies, removed immediately after sur-
gery, were immersed in 2-methylbutane on liquid nitro-
gen. Histological studies were performed on 4-mm thick
sections of the vessels and atheromatous plaque thaw-
mounted onto poly-L-lysine treated slides, cut in a cryo-
stat at -20°C. Tissues were then stained with Masson’s
trichrome and photographed under routine light micros-
copy (Leica Microsystems Ltd.).Figure 1 Histological sections of arteries, internal mammary (A) and p
femoral vein (C). The sections were stained with Masson’s trichrome andStatistical analysis
Results are expressed as mean ± standard deviation (SD).
The baseline clinical characteristics of each group were
analyzed by one-way analysis of variance (ANOVA). All
probability values were two-tailed, and all confidence
intervals were computed at the 95% level. Differences
were considered significant if the p value was less than
0.05. Chi-square analysis was used to compare the quali-
tative variables.
Relationships between cell biomarkers and continuous
variables were examined by Spearman correlation ana-
lysis, which measures the linear relation between two
quantitative variables (−1< r< 1). Multiple regression
models were used to correct for confounding factors to
assess the association between mRNA expression levels
of different biomarkers, risk factors or drugs. Statistical
analyses were performed with SPSS for Windows, ver-
sion 11.5 (IBM Corporation INC. Somers, NY (USA)).
Results
The baseline biological characteristics of the CMI and
PAOD patients are shown in Table (Variables are mean±
SD). No significant differences were found for any of
the variables studied between ICM and PAOD patients
(data not shown). In contrast, there were significant dif-
ferences in glycemia and HbA1c between well- and
poorly-controlled PAOD diabetic patients.
Histological characterization of vascular biopsies from
atherosclerotic patients
All vessel biopsies were stained with Masson’s trichrome
and photographed under light microscopy (Figure 1).
The IMA showed a normal histology with the adventi-
tia composed of connective tissue as well as collagen
and elastic fibers, the media layer composed of smooth
muscle and elastic fibers, and the intima layer, the inner
layer, composed of an elastic membrane lining and
smooth endothelium covered by elastic tissues
(Figure 1A).
The section corresponding to the OPA had soft pla-
ques with a lipid nucleus and calcium deposits. The cap-
sule had few collagen fibers and VSMC, although with
an excess of macrophages and lymphocytes (Figure 1B).opliteal artery (where the atheroma plaque is located) (B) and
photographed by routine light microscopy (4x).
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ventitia, media, intima layer and endothelium
(Figure 1C).
Both IMA and FV were composed of the same type of
layers, although IMA contained elastic layers that make
it more amenable to blood pressure variation.mRNA expression of different biomarkers in the vascular
system from atherosclerotic vessels of diabetic patients
To investigate the possible alteration in gene expression
of different biomarkers we analyzed mRNA levels in
IMA, OPA and FV from ICM and PAOD patients.
Expression was obtained from all the genes studied (46
genes), but only 9 genes were significantly different in all
tissues. These altered genes, which showed greater levels
in OPA compared to IMA or FV, were those involved in
thrombosis (F3 (tF): ref. sequence: NM_001993.2, assay
ID: Hs00175225_m1, amplicon length: 118), apoptosis
(CD83: ref. sequence: NM_004233.3, assay ID:
Hs00188486_m1, amplicon length: 104, MMP2: ref. se-
quence: NM_004530.2, assay ID: Hs00234422_m1, ampli-
con length: 83, MMP9: ref. sequence: NM_004994.2,
assay ID: Hs00234579_m1, amplicon length: 54, TIMP1:
ref. sequence: NM_003254.2, assay ID: Hs99999139_m1,
amplicon length: 55 and TIMP3: ref. sequence:
NM_000362.4, assay ID: Hs00165949_m1, amplicon
length: 59), lipid metabolism (LRP-1: ref. sequence:
NM_002332.2, assay ID: Hs00233856_m1, amplicon
length: 64 and NDUFA: ref. sequence: NM_002488.2,
assay ID: Hs00159575_m1, amplicon length: 65), and im-
mune response (TLR2: ref. sequence: NM_003264.3,
assay ID: Hs00610101_m1, amplicon length: 80). House-
keeping gene used were 18SrRNA (ref. sequence:
X03205.1, assay ID: Hs99999901_s1, amplicon length:
187) and GAPDH (ref. sequence: NM_002046.3, assay ID:
Hs99999905_m1, amplicon length: 122). (Figure 2).Protein expression of tF and LRP-1 in the vascular system
from atherosclerotic vessels of diabetic patients
The inflammatory process and lipid metabolism are two
of the key signaling pathways in the formation of athero-
mas in vascular wall. Therefore, and in view of the
results of mRNA expression obtained of two biomarkers
of these pathways (tF and LRP-1), we studied if this pat-
tern of overexpression showed in OPA, was repeated at
the protein level. We perform a Western blot analysis of
both markers, confirming this effect previously observed
with mRNA expression in all analyzed vessels. OPA had
greater protein expression of tF than the VF and the
control artery (IMA) (1.93 ± 0.12; 0.20 ± 0.12; 0.34 ± 0.23,
p<0.04, respectively). The same happened when we
study the levels of LRP-1. The OPA had greater protein
expression of LRP-1 than the VF and the control artery(IMA) (2.38 ± 0.11, 0.14 ± 0.07, 0.30 ± 0.17, p<0.05, re-
spectively). The results obtained are shown in Figure 3.
Correlation analysis between anthropometric and
biochemical parameters and biomarkers
Different anthropometric parameters (sex, age and blood
pressure) were correlated with the genes studied. In all
tissues (IMA, FV and OPA), only blood pressure showed
a significant correlation with different biomarkers. In
IMA biopsies, systolic blood pressure correlated nega-
tively with MMP-9, TIMP-1, TIMP-3, PPARg and
VEGFA mRNA expression (p=0.02, p=0.03, p=0.03,
p=0.03 and p=0.005, respectively). FV biopsies had a
positive correlation between diastolic blood pressure and
HIFA1A (p=0.04). OPA biopsies showed a positive cor-
relation between systolic blood pressure and MMP9
(p=0.03), and between diastolic blood pressure and
SREBP1 (p=0.02).
Of all the biochemical parameters studied, only fasting
blood glucose levels and HbA1c correlated significantly
with the biomarkers studied. IMA biopsies showed no
significant correlation with any of the biomarkers. How-
ever, FV biopsies showed a negative correlation between
glycemia levels and BCL2, CDKN1A, Cox2 and SREBP2
(p=0.02, p=0.04, p=0.05 and p=0.03, respectively).
HbA1c correlated negatively with BCL2 (p = 0.05). In
OPA biopsies only the glycemia levels were influential,
not the HbA1c. Fasting blood glucose levels showed a
positive correlation with CD83, LRP1, NDUFA2 and
TIMP1 (p=<0.0001, p=0.05 and p=0.03, respectively).
Influence of glycemic control on biomarker expression in
atherosclerotic and non-atherosclerotic vessels from type
2 diabetes mellitus patients
We classified diabetic patients into those with HbA1c
≤6.5 (good control; n = 6) and those with HbA1c >6.5
(poor control; n=9). Plasma glucose levels and HbA1c
were significantly higher in the poorly-controlled
patients (151.2 mg/dl ± 32.6 and 8.9% ± 1.3; p=0.02 and
p=<0.0001, respectively) versus well-controlled patients
(96.2 mg/dl ± 31.1 and 6.0% ± 0.4).
mRNA expression was obtained from FV or OPA to
compare the two diabetic groups (Figure 4). In FV, the
altered genes are involved in different process like apop-
tosis (BCL2: ref. sequence: NM_000633.2, assay ID:
Hs00608023_m1, amplicon length: 81 and CDKN1A: ref.
sequence: NM_078467.1, assay ID: Hs00355782_m1,
amplicon length: 66), lipid metabolism (NDUFA: ref. se-
quence: NM_002488.2, assay ID: Hs00159575_m1, ampli-
con length: 65), inflammation (COX2: ref. sequence:
NM_000963.1, assay ID: Hs00153133_m1, amplicon
length: 75) and transcription regulation (SREBP2: ref. se-
quence: NM_004599.2, assay ID: Hs00190237_m1, ampli-
con length: 141). These genes had greater expression
Figure 2 Expression of different genes in internal mammary artery (IMA), femoral vein (FV) and occluded popliteal artery (OPA) from
atherosclerotic patients with ICM or PAOD. (* p<0.05 vs control (IMA) ** p<0.05 vs control (IMA) and femoral vein).
Bernal-Lopez MR et al. Cardiovascular Diabetology 2012, 11:86 Page 6 of 11
http://www.cardiab.com/content/11/1/86
Figure 3 tF (F3) and LRP-1 expression levels in human vessels from atherosclerotic patients with ICM or PAOD. A.- Bar graphs showing
the densitometric analysis of showing tF bands (results are expressed as mean± SD. * p<0.04 vs FV or OPA, ** p<0.04 vs control (IMA) and FV)
and autoradiography showing tF (54 KDa) and β-actine (42 KDa) protein levels in internal mammary artery (IMA), femoral vein (FV) and occluded
popliteal artery (OPA) from two subjects from each vessel B.- Bar graphs showing the densitometric analysis of showing tF bands (results are
expressed as mean± SD. * p<0.05 vs FV or OPA, ** p<0.05 vs control (IMA) and FV) and autoradiography showing LRP-1 (85 KDa) and β-actine
(42 KDa) protein levels in internal mammary artery (IMA), femoral vein (FV) and occluded popliteal artery (OPA) from two subjects from each
vessel.
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only MMP-9 (ref. sequence: NM_004994.2, assay ID:
Hs00234579_m1, amplicon length: 54) mRNA expression
was increased in OPA from subjects with poor glycemic
control.
Discussion
In this study, IMA and FV had a similar gene expression
pattern but very different to that seen in OPA.
Atherosclerosis is the consequence of excess lipid ac-
cumulation in vessels, which triggers an immune re-
sponse, and the secretion of inflammatory cytokines
that promote its development. The arteries and veins
differ in that the atherosclerotic process is accentuated
in large arteries where hemodynamic forces are exerted.
We found significant differences between these differ-
ent vessels as result of an advanced atherosclerotic
process.
Lesion disruption facilitates the interaction between
circulating blood and prothrombotic substances, such as
tissue factor (tF) present within the atherosclerotic le-
sion. However, an increase of tF levels (mRNA and pro-
tein expression) was found in OPA with respect to IMA
or FV, in agreement with previous studies from coronary
arteries [10].
Our interest in inflammation as a component of CVD
led us to study other additional mediators, such as the
metalloproteinases (MMP), which form a family of zinc-
dependent endopeptidases that degrade vascularextracellular matrix and basement membrane compo-
nents playing a main role in tissue repair and vascular
remodelling. It is widely accepted that plaque rupture
plays a crucial role in the pathogenesis of vascular events
and that atherosclerotic plaque destabilization is
mediated by MMP. In the present study, we found
higher MMP2 and MMP9 mRNA in OPA. These find-
ings are consistent with previously published results
[11]. MMP2 and MMP9 are regulated by tissue inhibi-
tors, pro-inflammatory cytokines and other factors such
as oxLDL or situations of insulin resistance, where the
oxidative stress is increased [12], and they have both
pro- and anti-inflammatory actions. These actions are
associated with arterial stiffness and essential hyperten-
sion [13]. It was shown that MMP inhibitors and eNOS
inhibit the smooth muscle cells migration in vitro and
neointima formation in vivo [14]. Moreover, NO was
shown to attenuate gene expression associated with in-
sulin resistance [15].
As expected, gene expression levels of TIMP-1 and
TIMP-3, regulators of the cytoskeleton, were also
increased in OPA with respect to IMA and FV. TIMP-1
and TIMP-3 are endogenous inhibitors regulated by
oxLDL in vascular endothelial cells [16], and are com-
pensating mechanisms to prevent the breakdown of the
atheroma plaque.
Cholesterol and LDL concentrations have indubitable
value as risk markers for future cardiovascular events.
Recent studies have demonstrated that increased levels
Figure 4 Expression of different genes in femoral vein (A) and popliteal artery (B) from patients with PAOD, according to their HbA1c.
(* p<0.01 vs good glycemic control).
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tion, and that statins reduce inflammatory responses.
The relationship between lipid metabolism and poplit-
eal plaque has been poorly studied. In the present
study, NDUFA and LRP1 mRNA expression levels
were highly increased in occluded OPA. LRP1 is upre-
gulated by cardiovascular risk factors such as hyper-
cholesterolemia [17] and hypertension [18]. Aditionally,
this receptor contributes to the uptake of aggregated
LDL [19], one of the main modifications of LDL inthe arterial intima. The increase of LRP1 expression in
OPA (mRNA and protein expression) suggest that
LRP1 may play a crucial role in atherosclerosis pro-
gression, as previously demonstrated in other studies
[20,21].
Delivery of free fatty acids excess to peripheral tis-
sues can worsen insulin resistance and may play a role
in activating inflammatory processes through activation
of toll-like receptors [22]. TLRs are a family of pattern
recognition receptors found in various inflammatory
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artery compared with vessels without atheroma in our
study.
Different biomarkers were studied in the same envir-
onment, i.e., OPA and FV biopsies from the same dia-
betic patient. For this reason, it is very interesting to
study what happens with the biomarkers of different
metabolic pathways when the patient has good or poor
glycemic control. It is likely that hyperglycemia-induced
intra- and extra-cellular changes lead to alterations in
signal transduction pathways, affecting gene expression
and protein function and causing cell dysfunction and
damage. However, in patients with type 2 diabetes melli-
tus, pathways involved in the diffuse vasculopathy
present in non atherosclerotic arterial tissue and mRNA-
alterations are already established [24].
Our results demonstrated that patients with good gly-
cemic control had greater SREBP2 expression levels in
FV. Hyperinsulinemia is related to an up-regulation of
SREBPs [25], which could conflict with our results, but
we previously showed that SREBP2 controls the expres-
sion of some LDL receptor genes, such as CD36 gene
expression. A strong relation between SREBP2 and
CD36 was found in FV but not in OPA [26]. Sampson
et al. [27] showed that diabetic subjects with good gly-
cemic control had higher CD36 expression, which could
reflect a post-transcriptional efficiency of this receptor
and thus there would be greater metabolism of oxLDL
in these patients.
Our patients with good glycemic control showed an
increased expression from genes involved in protection
against apoptosis and cell turnover. Our data agree with
the results recently published by Redondo et al. (2011),
who demonstrated that there is a link between inflam-
mation (COX-2) and apoptosis resistance (BCL2) in the
vessels of diabetic patients [28].
Some drugs (e.g., metformin, thiazolidinediones and
statins) used in the treatment of diabetes and athero-
sclerosis are able to up-regulate both processes. These
may exert their protective effects through activation of
AMPK which has potentially beneficial anti-
atherosclerotic effects, such as reducing adhesion of in-
flammatory cells, lipid accumulation and the prolifera-
tion of inflammatory cells [29-31]. Recently, it has also
been shown that adiponectin receptors ADIPOR1 and
ADIPOR2, through the AMPK, may modify the risk of
CVD in individuals with IGT, possibly through altera-
tions in the mRNA expression levels [32]. Note that in
this year, AMPK has been proposed as a therapeutic tar-
get for diabetic vascular disease [33].
Results from the present study show that glycemic
control only exerts a significant effect on MMP-9 expes-
sion in OPA. These results are in agreement with previ-
ous studies showing that strict glycemic control doesnot improve cardiovascular disease progression in situa-
tions of advanced atherosclerosis [34,35].
Our study has certain limitations. The study popula-
tion consists of diabetic patients with advanced athero-
sclerosis. Therefore, results from the present study may
not be extrapolated to other population types. In
addition, the sample size was small, although the signifi-
cant differences found, contribute to the strength of the
results.
In conclusion, when we compared occluded arteries
with vessels without atheromas in diabetic and athero-
sclerotic patients we found significant differences in bio-
markers involved in inflammation, lipid metabolism and
apoptotic pathways. In addition, compensatory mechan-
isms could exist that prevent the rupture of the ather-
omatous plaque in peripheral arterial occlusive disease.
On the other hand, when the atherosclerotic process is
studied in terms of good or poor glycemic control into
the context of diabetes, we observed that the expression
of genes involved in inflammation and apoptosis protec-
tion was increased in veins from patients with good dia-
betic control. In contrast to veins, in arteries with
advanced thrombosis, like OPA, where lumen is almost
completely occluded, the glycemic control did not seem
to exert any effect on gene expression profile.
Abbreviations
ABCA1: ATP-binding cassette-family A member 1; AGER: Advanced
glycosylation end product-specific receptor; AKT1: v-akt murine thymoma
viral oncogene homolog 1; BAX: BCL2-associated X; BCL2: B-cell CLL/
lymphoma 2; BMI: Body mass index; Casp 3: Caspase 3; CCL2
(MCP1): Chemokine (C-C motif) ligand 2; CD34: Cluster of differentiation 34;
CD36: Cluster of differentiation 36; CD83: Cluster of differentiation 83;
CD86: Cluster of differentiation 86; CDKN1A: Cyclin-dependent kinase
inhibitor 1; CRP: C-reactive protein; CVD: Cardiovascular diseases; F3
(tF): Tissue factor; FV: Femoral vein; GAPDH: Glyceraldehyde 3 phosphate
dehydrogenase; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein
cholesterol; HIF1A: Hypoxia-inducible factor 1, alpha subunit;
HOMA: Homeostasis model assessment index; ICM: Ischemic
cardiomyopathy; IMA: Internal mammary artery; LDL: Low-density lipoprotein
cholesterol; LDLR: LDL Receptor; LRP1: Low density lipoprotein receptor-
related protein 1; MMP2: Metalloprotease 2; MMP3: Metalloprotease 3;
MMP9: Metalloprotease 9; MMP10: Metalloprotease 10;
MMP12: Metalloprotease 12; MMP13: Metalloprotease 13; NDUFA2: NADH
dehydrogenase 2 alpha; NKIRAS2: NFKB inhibitor interacting Ras-like 2;
OLR1: Oxidized Low Density Lipoprotein Receptor-1; OPA: Popliteal artery;
PAOD: Peripheral arterial occlusive disease; PPARg: Peroxisome proliferator-
activated receptor gamma; PTGS1 (Cox1): Prostaglandin endoperoxide
synthase 1; PTGS2 (Cox2): Prostaglandin-endoperoxide synthase 2;
SCARB1: Scavenger receptor class B member 1; Sp1: Specificity protein 1;
SREBF1: Sterol regulatory element binding transcription factor 1;
SREBF2: Sterol regulatory element binding transcription factor; TFPI: Tissue
factor pathway inhibitor; TIMP1: Tissue inhibitor of metalloproteinase 1;
TIMP3: Tissue inhibitor of metalloproteinase 3; TLR2: Toll-like receptor 2;
TLR4: Toll-like receptor 4; TP53: Tumor protein p53; USP9Y: Ubiquitin specific
peptidase 9, Y-linked; VEGFA: Vascular endothelial growth factor A.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MRBL and VLlC conceived the study, designed and performed the
experiments and prepared the manuscript. VGC, DLC, FC and RGH collected
Bernal-Lopez MR et al. Cardiovascular Diabetology 2012, 11:86 Page 10 of 11
http://www.cardiab.com/content/11/1/86the biochemical data from the patients. LB and FT oversaw manuscript
construction and supervised the experiments. All authors read and approved
the final manuscript.
Funding
This study was undertaken with finance from FIS “Centros de Investigación
En Red” (CIBER, CB06/03/0018) and REDINSCOR RD06/0003/0015 from
Instituto de Salud Carlos III, Madrid, Spain.
Acknowledgments
We thank Laura Nasarre for skillful technical assistance and the Internal
Medicine Department, Pathology Anatomy Department and Cardiovascular
Surgery Department (Carlos Haya Hospital, Malaga, Spain).
Author details
1Biomedical Research Laboratory, Endocrinology Department, Hospital Virgen
de la Victoria, Malaga, Spain. 2Cardiovascular Research Center, CSIC-ICCC,
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 3Internal Medicine
Department, Hospital Carlos Haya, Malaga, Spain. 4Cardiovascular Surgery
Department, Hospital Carlos Haya, Malaga, Spain. 5Ciber Fisiopatologia de la
Obesidad y Nutricion (CB06/003) Instituto de Salud Carlos III, Madrid, Spain.
Received: 2 July 2012 Accepted: 24 July 2012
Published: 24 July 2012
References
1. Suarez Munguia PJ: Release of nitric oxide induced by blood flow.
Update and perspectives of research. Arch Inst Cardiol Mex 2000, 70
(2):197–202.
2. Thomas DP, Roberts HR: Hypercoagulability in venous and arterial
thrombosis. Ann Intern Med 1997, 126(8):638–644.
3. Chiu JJ, Chien S: Effects of disturbed flow on vascular endothelium:
pathophysiological basis and clinical perspectives. Physiol Rev 2011, 91
(1):327–387.
4. Patel RS, Al Mheid I, Morris AA, Ahmed Y, Kavtaradze N, Ali S, Dabhadkar K,
Brigham K, Hooper WC, Alexander RW, Jones DP, Quyyumi AA: Oxidative
stress is associated with impaired arterial elasticity. Atherosclerosis 2011,
218(1):90–95.
5. Libby P, Ridker PM, Hansson GK: Progress and challenges in translating
the biology of atherosclerosis. Nature 2011, 473(7347):317–325.
6. Martinet W, Schrijvers DM, De Meyer GR: Necrotic cell death in
atherosclerosis. Basic Res Cardiol 2011, May 25. [Epub ahead of print].
7. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K, DECODE
Study Group: European Diabetes Epidemiology Group Prediction of the
risk of cardiovascular mortality using a score that includes glucose as a
risk factor. The DECODE Study. Diabetologia 2004, 47(12):2118–2128.
8. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-
glucose control with metformin on complications in overweight patients
with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854–865. Erratum
in: Lancet 1998; 352 (9139): 1558.
9. Bernal-Lopez MR, Llorente-Cortes V, Mayas MD, Lopez Carmona D, Gomez-
Huelgas R, Badimon L, Tinahones FJ: Modulation of human monocyte
CD36 by Type 2 Diabetes Mellitus and other atherosclerotic risk factors.
Eur J Clin Invest 2011, 41(8):854–862.
10. Karoly ED, Li Z, Dailey LA, Hyseni X, Huang YC: Up-regulation of tissue
factor in human pulmonary artery endothelial cells after ultrafine
particle exposure. Environ Health Perspect 2007, 115(4):535–540.
11. Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB,
Chung KC, Yoon SS, Chang DI: Plaque rupture is a determinant of
vascular events in carotid artery atherosclerotic disease: involvement of
matrix metalloproteinases 2 and 9. J Clin Neurol 2011, 7(2):69–76.
12. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C: Matrix
metalloproteinases: useful and deleterious. Biochem Soc Trans 2007,
35:689–691.
13. Zhou S, Feely J, Spiers JP, Mahmud A: Matrix metalloproteinase-9
polymorphism contributes to blood pressure and arterial stiffness in
essential hypertension. J Hum Hypertens 2007, 21(11):861–867.
14. Dey NB, Lincoln TM: Possible involvement of Cyclic-GMP-dependent
protein kinase on matrix metalloproteinase-2 expression in rat aortic
smooth muscle cells. Mol Cell Biochem 2012, .15. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M,
Tomaszewska R, Cooke JP, Dembinska-Kiec A: Increased nitric oxide
availability high fat diet metabolic alterations and gene expression
associated with insulin resistance. Cardiovasc Diabetol 2011, 10:68.
16. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF: Oxidized LDL differentially
regulates MMP-1 and TIMP-1 expression in vascular endothelial cells.
Atherosclerosis 2001, 156:119–125.
17. Llorente-Cortes V, Otero-Viñas M, Sanchez S, Rodriguez C, Badimon L: Low-
density lipoprotein upregulates low-density lipoprotein receptor-related
protein expression in vascular smooth muscle cells: possible
involvement of sterol regulatory element binding protein-2-dependent
mechanism. Circulation 2002, 106(24):3104–3110.
18. Sendra J, Llorente-Cortés V, Costales P, Huesca-Gómez C, Badimon L:
Angiotensin II upregulates LDL receptor-related protein (LRP1)
expression in the vascular wall: a new pro-atherogenic mechanism of
hypertension. Cardiovasc Res 2008, 78(3):581–589.
19. Llorente-Cortes V, Martínez-Gonzalez J, Badimon L: LDL receptor-related
protein mediates uptake of aggregated LDL in human vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol 2000, 20(6):1572–1579.
20. Hiltunen TP, Luoma JS, Nikkari T, Ylä-Herttuala S: Expression of LDL
receptor, VLDL receptor, LDL receptor-related protein, and scavenger
receptor in rabbit atherosclerotic lesions: marked induction of scavenger
receptor and VLDL receptor expression during lesion development.
Circulation 1998, 97(11):1079–1086.
21. Llorente-Cortes V, Otero-Viñas M, Berrozpe M, Badimon L: Intracellular lipid
accumulation, low-density lipoprotein receptor-related protein
expression, and cell survival in vascular smooth muscle cells derived
from normal and atherosclerotic human coronaries. Eur J Clin Invest 2004,
34(3):182–190.
22. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate
immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116
(11):3015–3025.
23. Carmody RJ, Chen YH: Nuclear factor-kappaB: activation and regulation
during toll-like receptor signaling. Cell Mol Immunol 2007, 4(1):31–41.
24. Skov V, Knudsen S, Olesen M, Hansen ML, Rasmussen LM: Global gene
expression profiling displays a network of dysregulated genes in non
atherosclerotic arterial tissue from patients with type-2 diabetes.
Cardiovasc Diabetol 2012, 11:15.
25. Xie X, Liao H, Dang H, Pang W, Guan Y, Wang X, Shyy JY, Zhu Y, Sladek FM:
Down-regulation of hepatic HNF4alpha gene expression during
hyperinsulinemia via SREBPs. Mol Endocrinol 2009, 23(4):434–443.
26. Bernal-Lopez MR, Llorente-Cortes V, Gomez-Huelgas R, Badimon L,
Tinahones FJ: Intimate relation between genic expression of scavenger
receptor CD36 and SREBP2. Proc Biochem 2010, 45(6):1002–1006.
27. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA: Increased expression
of a scavenger receptor (CD36) in monocytes from subjects with Type 2
diabetes. Atherosclerosis 2003, 167:129–134.
28. Redondo S, Ruiz E, Gordillo-Moscoso A, Navarro-Dorado J, Ramajo M,
Rodríguez E, Reguillo F, Carnero M, Casado M, Tejerina T: Overproduction
of cyclo-oxygenase-2 (COX-2) is involved in the resistance to apoptosis
in vascular smooth muscle cells from diabetic patients: a link between
inflammation and apoptosis. Diabetologia 2011, 54(1):190–199.
29. Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN: Simvastatin inhibits cell
cycle progression in glucose-stimulated proliferation of aortic vascular
smooth muscle cells by up-regulating cyclin dependent kinase inhibitors
and p53. Pharmacol Res 2008, 58(3–4):247–256.
30. Game BA, He L, Jarido V, Nareika A, Jaffa AA, Lopes-Virella MF, Huang Y:
Pioglitazone inhibits connective tissue growth factor expression in
advanced atherosclerotic plaques in low-density lipoprotein receptor-
deficient mice. Atherosclerosis 2007, 192(1):85–91.
31. Ewart MA, Kennedy S: AMPK and vasculoprotection. Pharmacol Ther 2011,
131(2):242–253.
32. Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Schwab U, Eriksson JG,
Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M:
Association of ADIPOR2 gene variants with cardiovascular disease and
type 2 diabetes risk in individual with impaired glucose tolerance: the
Finnish Diabetes Prevention Study. Cardiovasc Diabetol 2011, 10:83.
33. Ewart MA, Kennedy S: Diabetic cardiovascular disease? AMP-activated
protein kinase (AMPK) as a therapeutic target. Cardiovasc Hematol Agents
Med Chem 2012, [Epub ahead of print].
Bernal-Lopez MR et al. Cardiovascular Diabetology 2012, 11:86 Page 11 of 11
http://www.cardiab.com/content/11/1/8634. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998, 352:837–853.
35. Dluhy RG, McMahon GT: Intensive Glycemic Control in the ACCORD and
ADVANCE Trials. N Engl J Med 2008, 358:2630–2633.
doi:10.1186/1475-2840-11-86
Cite this article as: Bernal-Lopez MR et al.: Alterations of specific
biomarkers of metabolic pathways in vascular tree from patients with
Type 2 diabetes. Cardiovascular Diabetology 2012 11:86.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
